These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11807175)

  • 21. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinase inhibitors for treating cancer.
    Toogood PL
    Med Res Rev; 2001 Nov; 21(6):487-98. PubMed ID: 11607930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
    Hamdouchi C; Zhong B; Mendoza J; Collins E; Jaramillo C; De Diego JE; Robertson D; Spencer CD; Anderson BD; Watkins SA; Zhang F; Brooks HB
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1943-7. PubMed ID: 15780638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
    Prével C; Kurzawa L; Van TN; Morris MC
    Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
    Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
    Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
    Caridha D; Kathcart AK; Jirage D; Waters NC
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3863-7. PubMed ID: 20627564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
    McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
    J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological inhibitors of cyclin-dependent kinases.
    Knockaert M; Greengard P; Meijer L
    Trends Pharmacol Sci; 2002 Sep; 23(9):417-25. PubMed ID: 12237154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors.
    Arumugasamy K; Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():59-66. PubMed ID: 26231708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
    Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purine analogs as CDK enzyme inhibitory agents: a survey and QSAR analysis.
    Lee AD; Ren S; Lien EJ
    Prog Drug Res; 2001; 56():155-93. PubMed ID: 11417113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
    Law ME; Corsino PE; Narayan S; Law BK
    Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs.
    Hajdúch M; Havlíèek L; Veselý J; Novotný R; Mihál V; Strnad M
    Adv Exp Med Biol; 1999; 457():341-53. PubMed ID: 10500810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
    Cheng W; Yang Z; Wang S; Li Y; Wei H; Tian X; Kan Q
    Eur J Med Chem; 2019 Feb; 164():615-639. PubMed ID: 30639897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the Structural Basis for Inhibition of Cyclin-Dependent Kinases. New Pieces in the Molecular Puzzle.
    Levin NMB; Pintro VO; de Avila MB; de Mattos BB; De Azevedo WF
    Curr Drug Targets; 2017; 18(9):1104-1111. PubMed ID: 27848884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK inhibitors: from the bench to clinical trials.
    Rizzolio F; Tuccinardi T; Caligiuri I; Lucchetti C; Giordano A
    Curr Drug Targets; 2010 Mar; 11(3):279-90. PubMed ID: 20210753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
    Haesslein JL; Jullian N
    Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography.
    Knockaert M; Meijer L
    Biochem Pharmacol; 2002 Sep; 64(5-6):819-25. PubMed ID: 12213575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.